Juliana Alvarez Argote, MD
Assistant Professor
Locations
- Froedtert Hospital
- Zablocki VA Medical Center
Specialties
- Medical Oncology
- Benign Hematology
Languages
- Spanish
Education
- MD - Doctor of Medicine
Biography
Dr. Juliana Alvarez-Argote received her medical degree from the Universidad del Valle, Cali, Colombia. She completed her Internal Medicine Residency from the University of Connecticut, Farmington, CT. Afterwards, she obtained her Transfusion Medicine and Blood banking fellowship at the University of Chicago, Chicago, IL, and then completed her fellowship in hematology and medical oncology at the Medical College of Wisconsin, Milwaukee, WI. She is board certified in both internal medicine and transfusion medicine, and is board eligible in hematology and medical oncology.
Dr. Alvarez-Argote is currently an assistant professor in the division of hematology and medical oncology at the Medical College of Wisconsin and the Clement J. Zablocki VA Medical Center, both in Milwaukee, WI. Her professional interests include solid tumors, benign hematology, and gene therapy. She is currently part of a research project with Dr. Jeffrey Medin that focuses in gene therapy for sickle cell disease. She is a member of the Education Committee of the American Society of Gene and Cell Therapy.
Publications
-
(Benz S, Sherman KA, Dasanu CA, Alvarez-Argote J.) J Oncol Pharm Pract. 2024 Jun;30(4):697-704 PMID: 37350125 SCOPUS ID: 2-s2.0-85162616675 06/23/2023
-
(Wang X, McKillop WM, Dlugi TA, Faber ML, Alvarez-Argote J, Chambers CB, Wilber A, Medin JA.) J Gene Med. 2024 Jan;26(1):e3567 PMID: 37455676 SCOPUS ID: 2-s2.0-85165380220 07/17/2023
-
Pathophysiological characterization of the Townes mouse model for sickle cell disease.
(Alvarez-Argote J, Dlugi TA, Sundararajan T, Kleynerman A, Faber ML, McKillop WM, Medin JA.) Transl Res. 2023 Apr;254:77-91 PMID: 36323381 SCOPUS ID: 2-s2.0-85145313487 11/03/2022
-
(Dasanu CA, Alvarez-Argote J, Goff CB.) Expert Opin Pharmacother. 2022 Aug;23(11):1239-1241 PMID: 35703589 SCOPUS ID: 2-s2.0-85131928853 06/16/2022
-
Severe terminal ileitis induced by single-agent nivolumab administered every four weeks.
(Dasanu CA, Plaxe SC, Gupta V, Popescu IM, Grover M, Alvarez-Argote J.) J Oncol Pharm Pract. 2020 Sep;26(6):1516-1519 PMID: 32028838 SCOPUS ID: 2-s2.0-85079465900 02/08/2020
-
Durvalumab in cancer medicine: a comprehensive review.
(Alvarez-Argote J, Dasanu CA.) Expert Opin Biol Ther. 2019 Sep;19(9):927-935 PMID: 31272242 SCOPUS ID: 2-s2.0-85070812050 07/06/2019
-
Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
(Dasanu CA, Samara Y, Codreanu I, Limonadi FM, Hamid O, Alvarez-Argote J.) J Oncol Pharm Pract. 2019 Apr;25(3):638-647 PMID: 30253729 SCOPUS ID: 2-s2.0-85059350839 09/27/2018
-
Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
(Dasanu CA, Alvarez-Argote J, Limonadi FM, Codreanu I.) Expert Opin Biol Ther. 2019 Feb;19(2):99-104 PMID: 30556741 SCOPUS ID: 2-s2.0-85060297670 12/18/2018
-
(Alvarez Argote J, Dasanu CA.) Curr Med Res Opin. 2018 May;34(5):757-763 PMID: 28027687 SCOPUS ID: 2-s2.0-85045643814 12/29/2016
-
Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
(Dasanu CA, Alvarez-Argote J, Lippman SM, Plaxe SC.) J Oncol Pharm Pract. 2018 Apr;24(3):229-231 PMID: 28436313 04/25/2017
-
(Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA.) BBA Clin. 2016 Dec;6:12-8 PMID: 27331023 PMCID: PMC4900299 06/23/2016
-
Cancer-related microangiopathic hemolytic anemia.
(Choy B, Alvarez Argote J, Treml A.) Transfusion. 2016 Aug;56(8):1937 PMID: 27500918 SCOPUS ID: 2-s2.0-84982995109 08/09/2016